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Chronic cough is a distressing symptom for many people with pulmonary sarcoidosis. 
Continuous treatment with a macrolide antibiotic may improve cough. We aimed to assess 
the potential efficacy of azithromycin in patients with sarcoidosis and self-reported cough.  
 
Methods 
We did a non-controlled, open label clinical trial of azithromycin 250mg once daily for three 
months in patients with pulmonary sarcoidosis who reported a chronic cough. The primary 
outcome was number of coughs in 24 hours. Secondary outcomes were cough visual analog 
scales and quality of life measured using the Leicester Cough Questionnaire and King’s 
Sarcoidosis Questionnaire. Safety outcomes included QTc interval on ECG. Measurements 
were made at baseline and after one and three months of treatment. 
 
Results 
All 21 patients were white, median age 57 years, 9 males/12 females, median 3 years since 
diagnosis. Five were taking oral corticosteroids and none were taking other 
immunosuppressants. Twenty patients completed the trial. The median (range) number of 
coughs in 24h was 228 (43-1950) at baseline, 122 (20-704) at 1 month, and 81 (16-414) at 3 
months (p=.002, Friedman’s test). The median reduction in cough count at 3 months was 




In a non-controlled open-label trial in people with sarcoidosis who reported a chronic cough, 
3 months of treatment with azithromycin led to improvements in a range of cough metrics. 






People with sarcoidosis need treatment options that improve symptoms and quality of life, 
without causing undesirable side effects. Chronic cough is a distressing symptom for many 
patients with pulmonary sarcoidosis [1, 2]. Continuous treatment with the macrolide antibiotic 
azithromycin may improve cough, although strong evidence is lacking [3, 4]. Azithromycin is 
a cheap, readily available generic drug. In clinical trials in patients with chronic airways 
disease, continuous treatment with azithromycin for up to one year reduced exacerbations 
and was safe and well tolerated [4]. Whether azithromycin will benefit patients with 
sarcoidosis can only be answered definitively by a large randomized controlled trial (RCT). 
We conducted a single centre open label non-controlled clinical trial of azithromycin in 




The regional ethics committee (19/YH/0100) granted approval. The trial was registered on 
the European Union Drug Regulating Authorities Clinical Trials Database (EudraCT 2019-
000580-24). Patients were recruited from the sarcoidosis clinic at Hull University Teaching 
Hospitals NHS Trust. Eligibility criteria were a diagnosis of pulmonary sarcoidosis, >6 
months from diagnosis without evidence of self-resolving disease, and self-reported chronic 
cough attributed to sarcoidosis. Patients could be taking stable dose prednisolone ≤10mg 
daily and/or other immunomodulatory drugs. The main exclusion criteria were current long-
term macrolide therapy, allergy or intolerance to macrolide antibiotics, QTc prolongation on 
ECG (males >450ms, females >470ms), history of clinically significant cardiac arrhythmias, 
severe liver or kidney disease, or clinically meaningful bronchiectasis. All patients received 
oral azithromycin 250 mg once daily for 3 months. There was no placebo group.  
Assessments were performed at baseline and at 1 month and 3 months on azithromycin 
therapy. The primary endpoint was home-based 24-hour cough counting using the Hull 
automated cough counter with the Leicester software algorithm [5]. Secondary endpoints 
were visual analog scales (VAS, 0-100mm) for cough severity and urge to cough, and quality 
of life assessments relating to cough and sarcoidosis using the Leicester cough 
questionnaire (LCQ) and King’s sarcoidosis questionnaire (KSQ) respectively. KSQ scores 
for general health status (GH), lung, and combined lung_GH modules were calculated 
following transformation of raw scores to a linear logit scale [6]. This was an exploratory 
study designed to inform a future RCT and no sample size calculation was performed. 
Statistical analyses were performed using IBM SPSS v26. No imputation of missing data 
was performed and only participants with complete data were included in the repeated 
measures analyses. Subgroup analyses of cough counts were done using baseline cough 




Details of the 21 participants are shown in Table 1. Their median age was 57 years, 
comprising 9 men and 12 women. All patients were white, reflecting the local population. The 
consort diagram is shown in Figure 1. Twenty participants completed the trial. 
 
The median (range) number of coughs in 24h was 228 (43-1950) at baseline, 122 (20-704) 
at 1 month, and 81 (16-414) at 3 months (p=.002, Friedman’s non-parametric analysis of 
variance) (Figure 2). After 3 months of azithromycin therapy, the median percentage 
reduction in the number of coughs was 49.6%. To exclude the possibility that corticosteroid 
therapy affected cough responses, a sensitivity analysis of participants who were not taking 
oral steroids was performed which showed a similar result to the whole population (data not 
shown). 
 
There were improvements in cough severity VAS, urge to cough VAS, LCQ scores, and 
KSQ scores (Figure 3 and Table 2). For 19 participants with complete data at 3 months, 11 
(58%) had clinically meaningful improvements in LCQ score (minimum clinically important 
difference (MCID) ≥ 1.3 points [7]). Considering meaningful improvements in the KSQ [8], 15 
participants (79%) had an increase in KSQ_GH score of more than 8 points, 12 (63.2%) had 
an increase in KSQ_lung score of more than 4 points, and 13 (68.4%) had an increase in 
KSQ_lung_GH score of more than 5 points. Absolute changes in cough counts correlated 
with changes in LCQ (r=-0.637, r2=0.41, p=.003, Pearson’s correlation) and KSQ_GH (r=-
.587, r2=0.34, p=.008), but not with KSQ_lung or KSQ_lung_GH scores. 
 
We looked at the impact of baseline cough severity VAS scores on cough count and 
response to azithromycin therapy. Baseline cough count was significantly higher in patients 
with baseline cough severity VAS>40mm compared with <40mm (median 365 vs 125 
coughs in 24h, p=.001 (Mann Whitney U test). After 3 months of azithromycin therapy, the 
median percentage reduction in cough count was -78.8% in patients with baseline 
VAS>40mm compared with -40.6% in patients with baseline VAS<40mm (p=.057). 
 
Ten participants reported 16 adverse events, 11 mild and 5 moderate, one of which led to 
temporary interruption of azithromycin therapy. No participant had to stop treatment 
permanently because of adverse events. The most common adverse event was the common 
cold in 6 participants (the trial was conducted over the winter), with two of these reporting 
transient worsening cough. Two participants reported transient gastro-intestinal symptoms 
(stomach cramps, slight reduction in appetite). There were no serious adverse events. The 
median QTc interval on 12-lead ECG was 427ms (range 370-463) at baseline, 428ms (489-
461) at 1 month, and 435ms (497-468) at 3 months (p=.214). 
 
Discussion 
In this non-controlled open-label trial in people with sarcoidosis who reported a chronic 
cough, 3 months of treatment with azithromycin led to improvements in a range of cough 
metrics. The results support a RCT of azithromycin as a treatment for sarcoidosis cough. 
Current concepts link chronic cough with hypersensitivity of airway nerves or their central 
connections [9]. In sarcoidosis, Sinha et al reported that only cough reflex sensitivity was 
associated with objective cough frequency, and there was no association with lung function, 
number of organs involved, chest X-ray stage or serum angiotensin-converting enzyme [2]. 
Cough is an important patient-reported trial endpoint in sarcoidosis since it is a distressing 
and frequently disabling symptom for patients [2], and it may change more quickly and 
sensitively in response to treatment than lung function tests or radiology.  
An appealing strategy is to repurpose existing drugs that are safe for long-term use. 
Azithromycin has an acceptable tolerability profile when used for long-term treatment of 
chronic airways diseases [4]. Macrolide therapy has the potential to modulate cough through 
antibacterial or immunomodulatory effects or promoting oesophageal motility through motilin 
agonism. Azithromycin is preferable to other macrolide antibiotics because of its safety data 
for long term use, once daily administration, and minimal inhibition of liver CYP3A enzymes. 
 
More than half of the patients with sarcoidosis cough treated with azithromycin reported 
clinically meaningful improvements in cough-related quality of life as indicated by a ≥1.3 
point increase in LCQ score [7], and more than three quarters had clinically meaningful 
improvements sarcoidosis-related quality of life measured using the KSQ_GH score. 
Correlations estimated that 41% of the increase in LCQ and 34% of the increase in KSQ_GH 
could be attributed to reduction in the number of measured coughs. The KSQ lung module 
(alone as KSQ_lung or combined with general health as KSQ_lung_GH) was less 
responsive to changes in cough count, and only one of the six lung-related questions 
pertains to cough. Although cough counting has the perceived benefit of being an objective 
endpoint, our findings confirm that it correlates poorly with patient-reported outcomes. This 
will be an important consideration when designing a future randomised controlled trial that 
focuses on improving symptoms. 
 
The present study did not include a placebo arm, and a placebo response could explain 
some of the observed reduction in cough metrics. A modest but significant placebo response 
in subjective endpoints has been observed in a meta-analysis of clinical trials of inhaled 
corticosteroids for chronic cough [10]. In sarcoidosis cough, Du Bois’ study of inhaled 
fluticasone reported that in the placebo group, 4 point cough scores fell by 17% at 1-3 
months and 40% at 4-6 months [11]. The mean increase in LCQ in the present study (3.47 
points) following treatment with azithromycin compares favourably with changes in LCQ in 
published trials of azithromycin for chronic cough. In COPD patients with chronic cough, 
LCQ increased by mean 2.2 points with thrice-weekly azithromycin 250 mg for 12 weeks and 
by 0.9 points with placebo [12]. In treatment-resistant chronic cough, LCQ increased by 
mean 2.4 points with thrice-weekly azithromycin 250 mg for 8 weeks and by 0.7 points with 
placebo [13]. In the present study, the number of recorded coughs reduced by about half 
after 3 months of azithromycin therapy. Objective measurement of cough counting should be 
more resistant to placebo effect than subjective symptom scores [10]. There are no data in 
sarcoidosis specifically, but in a study of IPF cough Dutta et al reported that the mean 24h 
cough frequency in the placebo group fell by 8.8% (8.3/9.1) over the 90 day treatment period 
[14]. Birring et al reported stable 24h cough counts at day 14 in the placebo group in their 
study of inhaled PA101 in IPF cough [15], albeit in patients with more severe cough at 
baseline compared to our sarcoidosis cohort. Unlike IPF, sarcoidosis may naturally remit 
which accounts for many transitory successes claimed at one time or another for a variety of 
therapeutic interventions [16]. We deliberately chose to study patients with chronic stable 
pulmonary sarcoidosis (median 3 years since diagnosis) to minimise risk of confounding by 
natural disease resolution and regression to the mean. We believe that the magnitude of 
objectively measured cough reduction with azithromycin is greater than expected for a 
placebo response alone. 
 
Consideration should be given to inclusion criteria for a future RCT of azithromycin for 
sarcoidosis cough. We selected patients with self-reported chronic cough, and cough 
frequency in our cohort (median 10 coughs/h) was somewhat lower than trials which have 
used cough severity VAS≥40mm as an arbitrary inclusion criterion (typically around 20 
coughs/h). A baseline cough count of ≥15 coughs per hour has been used for trials in IPF 
cough [15]. The rationale is that selecting participants who have more severe cough will 
maximise the chance of detecting a meaningful benefit of therapy and optimise clinical trial 
efficiency. In our sarcoidosis trial cohort, subjects with baseline cough severity VAS≥40mm 
had significantly more coughs in 24h and a trend to larger reduction in cough counts in 
response to treatment, although the latter did not reach statistical significance (p=.057). On 
the other hand, only 8/21 (38%) or our trial participants had a baseline cough severity 
VAS≥40mm, which would restrict recruitment to a RCT compared with our broad inclusion of 
self-reported cough. It can be argued that for a treatment designed primarily to improve 
cough, patient-reported outcomes such as quality of life scores are more important trial 
endpoints than counting coughs. 
 
Azithromycin was well tolerated. The potential for macrolides to lengthen the QTc interval on 
ECG has not translated into risk of serious cardiac adverse events in several large trials of 
long term therapy in patients with chronic airways disease [4, 17]. The possibility of 
interaction with asymptomatic cardiac sarcoidosis needs to be considered when designing a 
future trial of azithromycin for sarcoidosis cough. The prevalence of occult cardiac 
involvement in sarcoidosis has been reported to be up to 25% as assessed using MRI [18]. 
However, whether the presence of incidental cardiac imaging abnormalities translates into 
increased arrhythmia risk that could be exacerbated by macrolide therapy is unknown. A 
pragmatic approach is to exclude subjects with a history of serious cardiac arrhythmias or 
abnormal QTc prolongation on ECG at screening, and to perform serial ECG monitoring.  
 
Both immunomodulatory and anti-bacterial properties of macrolides would be plausibly 
beneficial in sarcoidosis, but we do not know whether long term macrolide therapy could 
ameliorate granulomatous inflammation or reduce sarcoidosis progression. Improvements in 
sarcoidosis endpoints have been reported using antibiotic combinations that included 
azithromycin [19, 20]. In the present exploratory study, we were not aiming to demonstrate 
an effect on disease progression in patients taking azithromycin because of the sample size 
limitation of our single centre study and the imprecision of physiological endpoints such as 
change in FVC. A large RCT would be needed to study this. 
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TABLES 
Table 1. Demographic and clinical details of 21 recruited patients with sarcoidosis. Data are 







Years since diagnosis 
3 
(1-13) 
Scadding chest X-ray stage 1/2/3 
(n) 
1/7/13 
FEV1 percent predicted 
87.5 
(52-131) 










Oral corticosteroid therapy 
(n) 
5 






Number of coughs in 24 hours 
228 
(43-1950) 
Number of coughs per hour 
10 
(2-81) 








Leicester cough questionnaire score 
15.96 
(5.07-19.74) 





Table 2. Secondary endpoints 
Data are presented as median (range) and mean (standard deviation). KSQ, King’s sarcoidosis questionnaire (presented as general health (GH), lung, and 
combined lung-general health (GH) domains); LCQ, Leicester cough questionnaire; VAS, visual analog scale 
 Baseline 1 months 3 months 







Median 30.5 (9, 94) 
Mean 38.8 (25.7) 
24.0 (3, 88) 
33.7 (25.2) 
19.0 (0, 62) 
19.8 (17.7) 





Median 26.0 (8, 94) 
Mean 38.7 (26.2) 
26.0 (2, 83) 
32.5 (23.3) 
18.5 (0, 61) 
22.2 (18.3) 




Median 15.96 (5.07, 19.74) 
Mean 14.63 (4.07) 
17.6 (6.11, 20.75) 
16.68 (3.41) 
19.02 (14.93, 20.38) 
18.23 (1.76) 




Median 50.7 (23.8, 100) 
Mean 52.93 (18.3) 
61.9 (29.4, 100) 
63.0 (18.1) 
72.25 (39.9, 100) 
69.63 (15.4) 




Median 50.2 (29.0, 68.0) 
Mean 52.0 (10.4) 
52.6 (33.6, 77.1) 
54.5 (12.0) 
61.95 (41.6, 100) 
62.5 (14.0) 
6.5 (-1.3, 34.8) 
10.7 (11.3) 
.001 
KSQ_lung_GH Median 58.1 (36.7, 74.7) 58.7 (41.9, 86.1) 66.25 (50.1, 91.5) 10.7 (-2.3, 26.8) .0001 
Mean 57.3 (9.1) 61.9 (11.6) 67.58 (10.4) 10.6 (8.3) 
 
Figure legends 
Figure 1. Consort diagram 
 
Figure 2. Number of coughs in 24 hours. 
Individual subject data showing 24-hour cough counts at baseline and during treatment with 
azithromycin for 1 month and 3 months. 
 
Figure 3. Patient-reported outcomes. 
Individual subject data showing A) cough severity visual analog scale (VAS), B) urge to 
cough VAS, C) Leicester cough questionnaire (LCQ) scores, and D) King’s sarcoidosis 
questionnaire general health (KSQ_GH) scores at baseline and during treatment with 
azithromycin for 1 month and 3 months. VAS are 100mm scales with lower numbers 
indicating lower cough severity and urge to cough. Higher scores on LCQ and KSQ indicate 
better cough- and sarcoidosis-related quality of life respectively. 
  
 
  
 
  
 
